GlassScriptPhysician profile
Molly Williams
NPI 1457866253
$4,533.56
in general payments reported to CMS, 2019-2025
32 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $596 · 2023: $1,499 · 2024: $1,241 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.94 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $735.40 | 2021-2024 | Cardiomems |
| Pfizer INC. | $412.88 | 2021-2025 | |
| Novo Nordisk INC | $379.11 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $368.40 | 2021-2025 | |
| Amgen INC. | $303.93 | 2021-2025 | Repatha, Repatha |
| Organogenesis INC. | $278.59 | 2023-2025 | Affinity, Puraply Antimicrobial, Puraply Wound Matrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.45 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.80 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $169.80 | 2021-2024 | Xarelto |
| Integra Lifesciences Corporation | $155.39 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| E.R. Squibb & Sons, L.L.C. | $154.74 | 2022-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $120.26 | 2021-2023 | |
| Boston Scientific Corporation | $111.53 | 2023-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $99.30 | 2021-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $88.80 | 2021-2025 | Amvuttra, Onpattro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $63.14 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals, LTD. | $62.39 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $58.40 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $55.65 | 2024 | Arcalyst |
| Convatec INC. | $50.19 | 2024 | |
| Atricure, INC. | $49.02 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.51 | 2025 | |
| Lilly USA, LLC | $36.11 | 2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $34.34 | 2024-2025 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $31.69 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $29.70 | 2023-2024 | |
| Genzyme Corporation | $25.78 | 2024 | |
| Inspire Medical Systems, INC. | $24.74 | 2025 | Inspire |
| Cardiva Medical, INC. | $21.75 | 2024 | Cardiva Vascade 6/7f Vcs |
| Blue Earth Diagnostics | $19.24 | 2024 | |
| Glaxosmithkline, LLC. | $16.28 | 2025 | Shingrix |
| Fresenius Kabi USA, LLC | $16.25 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.